biopharma-reporter13d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
GlobalData on MSN13d
EMA accepts Alvotech and Advanz Pharma’s AVT05 MAA
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Alvotech and Advanz Pharma’s ...
Verywell Health on MSN4mon
4 Types of Biologics Used for Ulcerative Colitis
Medically reviewed by Mary Choy, PharmD Biologics work by targeting proteins that cause inflammation in ulcerative colitis.
European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...
Alvotech announces EMA acceptance of MAA for AVT05
Alvotech (ALVO) and Advanz Pharma announced that the European Medicines Agency has accepted a Marketing Authorization Application for AVT05, ...
PharmiWeb1mon
Johnson & Johnson transitions Remicade® (infliximab) and Simponi® (golimumab) for treatment of patients with Inflammatory Diseases
High Wycombe, UK, 17 October 2024 - Johnson & Johnson (J&J) announced today that it has now assumed all sales, marketing and distribution responsibility for Remicade® (infliximab) and Simponi® ...